1. Home
  2. KOSS vs MAIA Comparison

KOSS vs MAIA Comparison

Compare KOSS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

SELL

Current Price

$3.41

Market Cap

36.5M

ML Signal

SELL

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.30

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
MAIA
Founded
1953
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
79.0M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
KOSS
MAIA
Price
$3.41
$1.30
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.9K
363.2K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
55.56
33.33
EPS
N/A
N/A
Revenue
$13,020,773.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.14
N/A
52 Week Low
$3.37
$0.87
52 Week High
$5.91
$3.19

Technical Indicators

Market Signals
Indicator
KOSS
MAIA
Relative Strength Index (RSI) 39.06 43.99
Support Level N/A $1.24
Resistance Level $4.10 $1.48
Average True Range (ATR) 0.15 0.06
MACD 0.01 -0.01
Stochastic Oscillator 30.00 15.71

Price Performance

Historical Comparison
KOSS
MAIA

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: